AU2014352875B2 - Gastrin antagonists (eg YF476, netazepide) for treatment and prevention of osteoporosis - Google Patents

Gastrin antagonists (eg YF476, netazepide) for treatment and prevention of osteoporosis Download PDF

Info

Publication number
AU2014352875B2
AU2014352875B2 AU2014352875A AU2014352875A AU2014352875B2 AU 2014352875 B2 AU2014352875 B2 AU 2014352875B2 AU 2014352875 A AU2014352875 A AU 2014352875A AU 2014352875 A AU2014352875 A AU 2014352875A AU 2014352875 B2 AU2014352875 B2 AU 2014352875B2
Authority
AU
Australia
Prior art keywords
gastrin
bone
animals
ovx
ovariectomy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014352875A
Other languages
English (en)
Other versions
AU2014352875A1 (en
AU2014352875A8 (en
Inventor
Mark Kidd
Irvin Mark MODLIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CL Biosciences LLC
Original Assignee
CL Biosciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52118000&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2014352875(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by CL Biosciences LLC filed Critical CL Biosciences LLC
Publication of AU2014352875A1 publication Critical patent/AU2014352875A1/en
Publication of AU2014352875A8 publication Critical patent/AU2014352875A8/en
Application granted granted Critical
Publication of AU2014352875B2 publication Critical patent/AU2014352875B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2014352875A 2013-11-22 2014-11-21 Gastrin antagonists (eg YF476, netazepide) for treatment and prevention of osteoporosis Active AU2014352875B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361907980P 2013-11-22 2013-11-22
US61/907,980 2013-11-22
PCT/US2014/066832 WO2015077572A1 (en) 2013-11-22 2014-11-21 Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis

Publications (3)

Publication Number Publication Date
AU2014352875A1 AU2014352875A1 (en) 2016-05-26
AU2014352875A8 AU2014352875A8 (en) 2016-06-30
AU2014352875B2 true AU2014352875B2 (en) 2019-10-24

Family

ID=52118000

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014352875A Active AU2014352875B2 (en) 2013-11-22 2014-11-21 Gastrin antagonists (eg YF476, netazepide) for treatment and prevention of osteoporosis

Country Status (14)

Country Link
US (1) US10709714B2 (enExample)
EP (1) EP3071206B1 (enExample)
JP (1) JP6502939B2 (enExample)
KR (1) KR102254957B1 (enExample)
CN (1) CN106163527A (enExample)
AU (1) AU2014352875B2 (enExample)
BR (1) BR112016011727A2 (enExample)
CA (1) CA2929858C (enExample)
DK (1) DK3071206T3 (enExample)
ES (1) ES2870538T3 (enExample)
MX (1) MX2016006657A (enExample)
PL (1) PL3071206T3 (enExample)
RU (1) RU2693484C1 (enExample)
WO (1) WO2015077572A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10881667B2 (en) 2018-10-30 2021-01-05 City University Of Hong Kong Method and composition for treating epilepsy
US11285161B2 (en) 2019-04-26 2022-03-29 City University Of Hong Kong Method and composition for treating mental disorder and pain associated with nerve damage
CN110935005A (zh) * 2019-11-19 2020-03-31 宁波大学 一种丙谷二肽的新用途
CN115770266B (zh) * 2023-01-30 2023-05-09 云南中医药大学 一种用于治疗绝经后骨质疏松的药物组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993012817A1 (en) * 1991-12-20 1993-07-08 Warner-Lambert Company Therapeutic combinations useful in the treatment of gastroesophageal reflux disease
WO2005007107A2 (en) * 2003-07-11 2005-01-27 University Of Massachusetts Histamine and cck2/gastrin receptor blockade in the treatment of acid-peptic disease and cancer

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989005812A1 (fr) 1987-12-22 1989-06-29 Yoshitomi Pharmaceutical Industries, Ltd. Composes de thienodiazepine et leur utilisation en medecine
DE69017302T3 (de) 1989-08-04 1999-08-05 Merck Sharp & Dohme Ltd., Hoddesdon, Hertfordshire Zentrale Cholecystokinin-Antagonisten zur Behandlung von psychiatrischen Krankheiten.
US5399565A (en) 1990-07-17 1995-03-21 Eli Lilly And Company Pyrazolidinone CCK and gastrin antagonists and pharmaceutical formulations therof
HUT67299A (en) 1990-12-25 1995-03-28 Yamanouchi Pharma Co Ltd Novel benzodiazepine derivetives, pharmaceutical compositions contaning them and process for their producing
CZ282536B6 (cs) 1991-07-12 1997-08-13 Warner-Lambert Company Nepřirozený dipeptoid pro výrobu léčiva pro prevenci a léčbu záchvatů panického strachu
CA2120939A1 (en) 1991-10-11 1993-04-15 Tetsuya Tahara Therapeutic agent for osteoporosis and diazepine compound
IL104853A (en) 1992-02-27 1997-11-20 Yamanouchi Pharma Co Ltd Benzodiazepine derivatives, their preparation and pharmaceutical compositions containing them
JP3419539B2 (ja) 1993-02-17 2003-06-23 中外製薬株式会社 インドリン−２−オン誘導体
GB2282595A (en) 1993-08-25 1995-04-12 Yamanouchi Pharma Co Ltd Benzodiazepine derivatives
IT1261255B (it) 1993-09-09 1996-05-09 Rotta Research Lab Derivati acidi poliamidici ad attivita' antigastrinica, procedimento per la loro preparazione e loro uso farmaceutico.
EP0869975B1 (en) 1995-12-11 2007-08-15 New England Medical Center Hospitals, Inc. Assay for and uses of peptide hormone receptor ligands
US5750353A (en) 1995-12-11 1998-05-12 New England Medical Center Hospitals, Inc. Assay for non-peptide agonists to peptide hormone receptors
US5922883A (en) 1996-04-03 1999-07-13 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US20040001842A1 (en) 1997-05-12 2004-01-01 Dov Michaeli Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors
ES2227833T3 (es) 1997-05-12 2005-04-01 Aphton Corporation Composiciones inmunogenicas para el receptor cck-b/gastrina y metodos para el tratamiento de tumores.
EP1076561B1 (en) 1998-05-15 2005-03-30 Aphton Corporation Combination therapy for the treatment of tumors
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
IL139811A0 (en) 1998-06-04 2002-02-10 Abbott Lab Cell adhesion-inhibiting antinflammatory compounds
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
DE60016384T2 (de) 1999-01-29 2005-12-01 Chugai Seiyaku K.K. Chondrogonese promotoren und indolin-2-on derivate
WO2000075145A1 (en) 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US20030191279A1 (en) 1999-08-27 2003-10-09 Goldstein Steven Wayne Urea derivatives useful as anticancer agents
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
ES2259617T3 (es) 1999-11-05 2006-10-16 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Compuestos heterociclicos y su aplicacion como medicamentos.
WO2001035899A2 (en) 1999-11-19 2001-05-25 Axxima Pharmaceuticals Ag Inhibitors of helicobacter pylori induced gastrointestinal diseases
AU2001253024A1 (en) 2000-04-10 2001-10-23 The General Hospital Corporation Diagnosis and treatment of gastrointestinal disease
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
AU2002252456A1 (en) 2001-03-23 2002-10-08 Aphton Corporation Combination treatment of pancreatic cancer
EP1391211A1 (en) 2001-04-27 2004-02-25 Chugai Seiyaku Kabushiki Kaisha Chondrogenesis promoters
US20090191232A1 (en) 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
CA2445477A1 (en) 2001-05-11 2002-11-21 Yamanouchi Pharmaceutical Co., Ltd. Antitumor agents
AUPR738301A0 (en) 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
CN100348196C (zh) 2001-11-13 2007-11-14 詹姆士布莱克基金会有限公司 作为胃泌激素和缩胆囊肽受体配体的苯并三氮杂䓬
EP1478357B1 (en) 2002-02-19 2007-01-31 Pfizer Italia S.r.l. Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
DE10207037A1 (de) 2002-02-20 2003-08-28 Bayer Cropscience Gmbh 2-Amino-4-bicyclyamino-6H-1,3.5-triazine, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
UA79804C2 (en) 2002-07-03 2007-07-25 Janssen Pharmaceutica Nv Cck-1 receptor modulators
US20030049698A1 (en) 2002-10-08 2003-03-13 Wang Timothy C. Diagnosis and treatment of gastrointestinal disease
CA2520546A1 (en) 2003-03-28 2005-02-10 Janssen Pharmaceutica, N.V. Benzo[1,2,5]thiadiazole compounds
GB0310865D0 (en) 2003-05-12 2003-06-18 Black James Foundation Gastrin and cholecystokinin receptor ligands
WO2004101533A1 (en) 2003-05-12 2004-11-25 Janssen Pharmaceutica, N.V. 1, 3, 4-benzotriazepin-2-one salts and their use as cck receptor ligands
CA2534887A1 (en) 2003-08-08 2005-02-24 Janssen Pharmaceutica, N.V. Process for the preparation of 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds
US20070293482A1 (en) 2004-03-19 2007-12-20 Novartis Pharmaceuticals Corporation Process for Preparing Benzodiazepines
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
US7947833B2 (en) 2004-08-04 2011-05-24 Janssen Pharmaceutica Nv Preparation of quinoxaline compounds
MX2007003623A (es) 2004-09-24 2007-09-11 Johnson & Johnson Compuestos sulfonamida.
EP1817333A4 (en) 2004-10-12 2008-12-31 Janssen Pharmaceutica Nv CHOLECYSTOKININ-1 RECEPTOR MATERIALS OF DOGS AND THEIR USE
WO2006049941A2 (en) 2004-10-27 2006-05-11 Neurogen Corporation Diaryl ureas as cb1 antagonists
WO2006052542A2 (en) 2004-11-04 2006-05-18 Neurogen Corporation Arylalkyl ureas as cb1 antagonists
GB0425196D0 (en) 2004-11-15 2004-12-15 Black James Foundation Gastrin and cholecystokinin receptor ligands
WO2006064339A1 (en) 2004-12-17 2006-06-22 Pfizer Japan Inc. Chromane derivatives useful as acid pump antagonists
US20080161293A1 (en) 2005-01-19 2008-07-03 Zeria Pharmaceutical Co., Ltd. Antitumor Agent
AR053713A1 (es) 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
JP5197361B2 (ja) 2005-06-06 2013-05-15 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ 睡眠障害を処置するための組成物および方法
WO2006134460A1 (en) 2005-06-14 2006-12-21 Pfizer Japan Inc. Chromane substituted benzimidazole derivatives as acid pump antagonists
DE602005013372D1 (de) 2005-07-29 2009-04-30 Rottapharm Spa Kombination aus Itriglumid und PPI zur Behandlung von gastrointestinalen- und assozierten Krankheiten
WO2007026218A2 (en) 2005-09-01 2007-03-08 Pfizer Japan Inc. Chromane substituted 2-alkyl imidazopyridine derivatives and use thereof as acid pump antagonists
WO2007031860A1 (en) 2005-09-15 2007-03-22 Pfizer Japan Inc. Indane substituted benzimidazoles and their use as acid pump inhibitors
WO2007072142A2 (en) 2005-12-19 2007-06-28 Pfizer Japan Inc. Benzimidazole-5-carboxamide derivatives
BR122020004679B1 (pt) 2005-12-19 2021-09-21 Raqualia Pharma Inc Composição farmacêutica
KR20080108129A (ko) 2006-03-17 2008-12-11 라퀄리아 파마 인코포레이티드 크로메인 유도체
EP2004631A1 (en) 2006-04-12 2008-12-24 Merck Patent GmbH N-oxides of heterocyclic substituted bisarylureas for treating kinase-mediated diseases
FR2901472B1 (fr) 2006-05-24 2010-08-13 Oreal Procede de defrisage des fibres keratiniques avec un moyen de chauffage et des agents denaturants
FR2901473B1 (fr) 2006-05-24 2010-08-13 Oreal Procede de defrisage des fibres keratiniques avec un moyen de chauffage et une amide
WO2008035195A1 (en) 2006-09-21 2008-03-27 Raqualia Pharma Inc. Benzimidazole derivatives as selective acid pump inhibitors
WO2008046082A2 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Use of heterocyclic compounds as therapeutic agents
WO2008059373A1 (en) 2006-11-17 2008-05-22 Raqualia Pharma Inc. Imidazo [1, 2-a] pyrazine derivatives and their use as acid pump antagonists
JP2008222557A (ja) 2007-03-08 2008-09-25 Kotobuki Seiyaku Kk ピロロ［３，２−ｄ］ピリミジン誘導体及びこれを有効成分とする医薬組成物
WO2008114123A1 (en) 2007-03-21 2008-09-25 Raqualia Pharma Inc. Spiro benzimidazole derivatives as acid pump inhibitors
WO2008124524A2 (en) 2007-04-03 2008-10-16 Janssen Pharmaceutica N.V. Aryl sulfonamide compounds as modulators of the cck2 receptor
WO2008124518A1 (en) 2007-04-03 2008-10-16 Janssen Pharmaceutica N.V. Oxo-dihydroisoindole sulfonamide compounds as modulators of the cck2 receptor
JP5492770B2 (ja) 2007-06-26 2014-05-14 サノフイ ベンゾイミダゾール及びアザベンゾイミダゾールの位置選択的銅触媒合成
RU2379043C2 (ru) 2007-08-02 2010-01-20 Закрытое акционерное общество "Биологические исследования и системы" Фармацевтическая композиция для профилактики и лечения остеопороза у женщин в период менопаузы
WO2009020768A1 (en) 2007-08-07 2009-02-12 President And Fellows Of Harvard College Targeting the oncoprotein nucleophosmin
TW201011009A (en) 2008-09-15 2010-03-16 Priaxon Ag Novel pyrrolidin-2-ones
WO2010036316A1 (en) 2008-09-24 2010-04-01 Yangbo Feng Urea and carbamate compounds and analogs as kinase inhibitors
BRPI1009145A2 (pt) 2009-03-31 2016-04-19 Zeria Pharm Co Ltd método para a fabricação de derivado de benzodiazepina
MX2012000275A (es) 2009-07-09 2012-02-08 Raqualia Pharma Inc Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
CA2775204A1 (en) 2009-09-24 2011-03-31 Centro Nacional De Investigaciones Oncologicas (Cnio) Fused imidazo [3, 2 - d] pyraz ines as pi3 kinase inhibitors
RU2017109664A (ru) 2009-10-06 2019-01-23 Милленниум Фармасьютикалз, Инк. Гетероциклические соединения, используемые в качестве ингибиторов pdk1
AU2010319298B2 (en) 2009-11-13 2015-11-05 Plastipak Packaging, Inc. Oxygen scavengers, compositions comprising the scavengers, and articles made from the compositions
WO2011063164A2 (en) 2009-11-18 2011-05-26 Steady Sleep Rx Co., Inc. Sustained release cannabinoid medicaments
WO2011133722A2 (en) 2010-04-23 2011-10-27 Kineta, Inc. Anti-viral compounds
US9000054B2 (en) 2010-08-12 2015-04-07 Senomyx, Inc. Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer
US20120231083A1 (en) 2010-11-18 2012-09-13 The Board Of Trustees Of The University Of Illinois Sustained release cannabinoid medicaments
EP2640379A4 (en) 2010-11-18 2014-08-13 Pier Pharmaceuticals LOW DOSED CANNABINOIDARY MEDICINES
WO2012080729A2 (en) 2010-12-14 2012-06-21 Electrophoretics Limited CASEIN KINASE 1δ (CK1δ) INHIBITORS
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
WO2013017479A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
RU2634708C9 (ru) 2011-11-07 2018-05-11 Массачусетс Инститьют Оф Текнолоджи Оксоалкилиденовые комплексы вольфрама для z-селективного метатезиса олефинов
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
TWI610916B (zh) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993012817A1 (en) * 1991-12-20 1993-07-08 Warner-Lambert Company Therapeutic combinations useful in the treatment of gastroesophageal reflux disease
WO2005007107A2 (en) * 2003-07-11 2005-01-27 University Of Massachusetts Histamine and cck2/gastrin receptor blockade in the treatment of acid-peptic disease and cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Berna, M et al (2007) Curr Top Med Chem 7(12): 1211-1231 *
Boyce, M et al (2012) British Journal of Clinical Pharmacology 76: 689-698 *
Fossmark, R et al (2012) Aliment Pharmacol Ther 36: 1067–1075 *

Also Published As

Publication number Publication date
BR112016011727A2 (pt) 2017-08-08
JP2016538295A (ja) 2016-12-08
WO2015077572A1 (en) 2015-05-28
RU2016124538A (ru) 2017-12-27
AU2014352875A1 (en) 2016-05-26
PL3071206T3 (pl) 2022-01-17
CN106163527A (zh) 2016-11-23
US20150148339A1 (en) 2015-05-28
EP3071206A1 (en) 2016-09-28
EP3071206B1 (en) 2021-02-17
ES2870538T3 (es) 2021-10-27
KR102254957B1 (ko) 2021-05-25
DK3071206T3 (da) 2021-05-25
RU2693484C1 (ru) 2019-07-03
CA2929858A1 (en) 2015-05-28
MX2016006657A (es) 2016-10-12
JP6502939B2 (ja) 2019-04-17
CA2929858C (en) 2022-03-29
AU2014352875A8 (en) 2016-06-30
US10709714B2 (en) 2020-07-14
KR20160088891A (ko) 2016-07-26

Similar Documents

Publication Publication Date Title
Tabatabaei-Malazy et al. New horizons in treatment of osteoporosis
Bitto et al. Effects of genistein aglycone in osteoporotic, ovariectomized rats: a comparison with alendronate, raloxifene and oestradiol
Battaglino et al. Spinal cord injury-induced osteoporosis: pathogenesis and emerging therapies
Lee et al. NPY regulation of bone remodelling
Salari Sharif et al. Current, new and future treatments of osteoporosis
Kok et al. Secondary osteoporosis in patients with an osteoporotic fracture
Israeli et al. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy
Tando et al. Hif1α is required for osteoclast activation and bone loss in male osteoporosis
AU2014352875B2 (en) Gastrin antagonists (eg YF476, netazepide) for treatment and prevention of osteoporosis
Mazid Helali et al. Cathepsin K inhibitors: a novel target but promising approach in the treatment of osteoporosis
Thomas Intermittent parathyroid hormone therapy to increase bone formation
Xu et al. Effects of different dosages of parathyroid hormone-related protein 1–34 on the bone metabolism of the ovariectomized rat model of osteoporosis
Di Bella et al. Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonin, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: a preliminary report
ESHRE Capri Workshop Group Bone fractures after menopause
Min et al. The decline of whole-body glucose metabolism in ovariectomized rats
Davidge-Pitts et al. Transgender bone health
Watanabe et al. Ibandronate concomitantly blocks immobilization-induced bone and muscle atrophy
Abo-Elenin et al. An overview of osteoporosis and possible treatment approaches
Kanda et al. Effect of the antidiabetic agent pioglitazone on bone metabolism in rats
Stathopoulos et al. A review on osteoporosis in men
Appelman-Dijkstra et al. Prevention of incident fractures in patients with prevalent fragility fractures: Current and future approaches
Rekasi et al. Regulation of prostate‐specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone‐releasing hormone and vasoactive intestinal peptide
Jiang et al. An overview of osteoporosis management
HK1230487A1 (en) Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis
Mohanty et al. Molecular mechanisms and treatment strategies for estrogen deficiency-related and glucocorticoid-induced osteoporosis: a comprehensive review

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 30 , NO 21 , PAGE(S) 3064 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME CL BIOSCIENCES LLC, APPLICATION NO. 2014352875, UNDER INID (71) CORRECT THE APPLICANTS NAME TO CL BIOSCIENCES LLC

FGA Letters patent sealed or granted (standard patent)